New NASDAQ Stock Profile (BSGM) Exhibits Over 150% Potential Upside To Analyst's $11 Target
Major Announcement Released Today - Details Below
The market is now open and there is zero time to waste...
Today's new stock profile is low float NASDAQ idea:
BioSig Technologies, Inc. (BSGM)
BioSig Technologies, Inc., a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals.
Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures. It is also developing a library of software tools that are designed to be configured to fit the needs of electrophysiologists in various settings and for arrhythmia treatments. The company was founded in 2009 and is headquartered in Los Angeles, California.
Today, the company made a major announcement. Check it out:
BioSig Completes 100th Patient Case with PURE EP(TM) System
WESTPORT, Feb 19, 2020 (GLOBE NEWSWIRE via COMTEX) -- WESTPORT, Feb. 19, 2020 (GLOBE NEWSWIRE) --
- Commercialization and install plan ahead of schedule
- Installations at new centers are driving patient enrollments and clinical data collection
BioSig Technologies, Inc. BSGM, ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company successfully completed 100 patient cases with its PURE EP(tm) System.
Read the full article here.
BSGM is displaying a staggering amount of upside potential backed by important catalysts. Read up.
#1 BSGM Catalyst - Analyst $11.00 Price Target
Laidlaw & Company has provided an $11.00 price target on BSGM on 2/20/19 according to MarketBeat's website.
From its current $4.00+ share price, this provides BSGM with over 150% in potential upside.
Don't forget, it was only last week when I brought GNPX to your attention with a $5.00 price target which it hit in only 4 days after running over 250%.
Could this be the next NASDAQ stock to follow suit? It may only take one big news catalyst to set this stock on that journey.
Additionally, Yahoo Finance reports BSGM to have a float in the 15Mn share range.
Though that number is slightly higher than some other recent runners I've delivered, it is still on the low side which means volatility could be a real possibility (if the right catalyst comes along).
#2 BSGM Catalyst - PURE EP (tm) System Installed At Mayo Clinic In Florida
BioSig to Commence Patient Cases at Mayo Clinic
Second institution to begin patient enrollments with PURE EP(TM) System
Westport, CT, Jan. 16, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company installed its PURE EP(tm) System at Mayo Clinic in Florida.
Mayo Clinic is the second institution to conduct patient cases under BioSig’s clinical trial titled “Novel Cardiac Signal Processing System for Electrophysiology Procedures (PURE EP 2.0 Study)”. Patient enrollments are due to begin mid-January 2020. Texas Cardiac Arrhythmia Research Foundation (TCARF) in Austin, Texas, was the first institution to conduct patient cases under the clinical trial in the fourth quarter of 2019.
#3 BSGM Catalyst - Awarding Of Additional Patent
BioSig Awarded Additional US Patent Claims for its PURE EP(TM) System
Westport, CT, Jan. 14, 2020 (GLOBE NEWSWIRE) --
- Company allowed a fifth utility patent
- Claims address methods for removing voltage offset from biomedical signals
- Eleven additional patent applications covering PURE EPTM System are currently pending
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the US Patent Office allowed a fifth utility patent covering its PURE EP(TM) System. The recently allowed patent application number 16/195,562 entitled "APPARATUS AND METHODS FOR REMOVING A LARGE-SIGNAL VOLTAGE OFFSET FROM A BIOMEDICAL SIGNAL" was filed on November 19, 2018. The claims address methods for removing a voltage offset from a biomedical signal, such as low amplitude cardiac signals during an ablation procedure in the presence of noise.
The allowed patent application complements BioSig’s expanding patent portfolio, which now includes five allowed/issued patents. Eleven additional worldwide utility patent applications are pending covering various aspects of its PURE EP(TM) System for recording, measuring, calculating and displaying of electrocardiograms during cardiac ablation procedures. BioSig also has 21 allowed/issued worldwide design patents, which cover various features of its display screens and graphical user interface for enhanced visualization of biomedical signals.
"We are pleased to announce this newest patent allowance, which further acknowledges the novelty of our advanced biomedical signal processing technology,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.
The PURE EP(TM) System is indicated as a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data.
More About BioSig Technologies, Inc.
From the company website:
BioSig: A Pioneer in Signal Processing Solutions
At BioSig, we're working to develop and deliver the advanced signal processing solutions that will unlock the future of bioelectronic medicine, starting with the PURE EP™ System.
We built BioSig to achieve this vision – with a strong commitment to research, a world-class leadership team, and a network of expert partners. We are now achieving important milestones as we prepare to enter the fast-growing electrophysiology market, but our aspirations reach even further: to lead one of the most innovative and most promising frontiers in healthcare.
Our Path from Research to Growth
Since our founding in 2009, BioSig has built an impressive scientific and business track record. In less than 10 years, we have developed a first-of-its-kind technology, attracted significant investment, conducted pre-clinical studies with centers of excellence, signed a 10-year strategic agreement with Mayo Clinic, and developed a robust IP strategy.
We are now poised to commercialize our first product: the PURE EP™ System. In 2018, we received FDA 510(k) clearance for PURE EP™, began market launch, and BioSig was uplisted to the NASDAQ national exchange. In 2019, we plan to begin first-in-human trials, introduce PURE EP™ to medical centers nationwide, collect our first revenues, and further develop our IP and R&D. Looking further ahead, we expect to publish trial results, grow internationally, and expand our product pipeline.
Tapping the Fast-Growing EP Market
Initially, we are targeting the $4.6Bn electrophysiology (EP) market, which is growing at more than 10% annually and expected to exceed $8.5Bn by 2024*. Ultimately, we hope to expand the applications of our technology to new disease areas and markets - helping to bring the promise of bioelectronic medicine to millions of patients worldwide.
Building for the Long Term
We are building BioSig for long-term impact and growth. This intent guides every decision we've made: from our culture and team to our financing and research. Our goal is nothing less than to transform the treatment of the most challenging diseases today.
To achieve this goal, we have created a culture that values the highest quality work, thorough research and scientific expertise, and deep collaboration with leaders in our field. Our exceptional culture and ambitious vision are already attracting high-powered new hires and partners for the next stage of our growth.